newsfilter
← Latest News
GlobeNewswire·

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

ALACHUA, Fla. and TAMPA, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal